Theralase(R) Closes $CAN 2.66 Million Financing

Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has successfully closed both a non-brokered private placement offering ("Offering") of units ("Units") and a Line Of Credit ("LOC"). On closing of the Offering, the Corporation issued an aggregate of 6,404,700 Units at a price of $CAN 0.26 per Unit for aggregate gross proceeds of $CAN 1,665,222.